Localization of the therapeutic targets for endothelin receptor antagonists and sodium-glucose co-transporter 2 inhibitors in the chronic liver disease, primary sclerosing cholangitis
Both drug targets were retained in the key hallmarks of PSC pathology; ET<sub>A</sub> and SGLT2 staining within cholangiocytes undergoing ductal transformation and cells within the fibrotic septa, supporting the proposed benefit of combination treatment strategy.
Authors
- Anna Paterson (ORCID: https://orcid.org/0000-0002-1494-0875)
- William Gelson (ORCID: https://orcid.org/0000-0001-8056-4364)
- Janet J. Maguire (ORCID: https://orcid.org/0000-0002-9254-7040)
- Peter J. Greasley (ORCID: https://orcid.org/0000-0002-2529-4477)
- Phil Ambery (ORCID: https://orcid.org/0000-0003-2978-1886)
- Thomas L. Williams (ORCID: https://orcid.org/0000-0003-3288-9513)
- Anthony P. Davenport (ORCID: https://orcid.org/0000-0002-2096-3117)
- Rhoda E. Kuc
Institutions
- University of Cambridge (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- AstraZeneca (Sweden) (SE)
- Addenbrooke's Hospital (GB)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.3389/fphar.2025.1680875
- Primary Topic
- Liver Diseases and Immunity
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wellcome Trust
- National Institute for Health and Care Research
- Department of Health and Social Care
- NIHR Cambridge Biomedical Research Centre